BC007 now has 75% of patients enrolled

New press release from Berlin Cures:

  • 75% of required patients are now enrolled in the phase 2 trial for BC007
  • Prof. Scheibenbogen of Charite University Hospital, Germany leading CFS/Long covid expert joins their advisory board